P168 Factors associated with adverse outcomes in uveitis related to spondylarthritis (SpA-U) - development of a prognostic outcome score in patients with SpA-U

Abstract

Abstract Background/Aims Uveitis is the most frequent extra-articular manifestation of spondylarthritis (SpA), characterised by a sudden onset, often unilateral, anterior and recurrent, and may be the first clinical manifestation of the disease. The lack of standardised and validated outcome measures in uveitis makes it difficult to evaluate the efficacy of and refractoriness to treatment and determine factors associated with adverse outcomes. The objective of our study was to develop a prognostic outcome score for patients with uveitis associated with spondylarthritis (SpA-U) and determine factors associated with adverse outcomes in uveitis associated with SpA-U in patients under systemic treatment. Methods The outcome score was defined by best-corrected visual acuity (BCVA), anterior chamber inflammation, macular edema and inflammation of posterior chamber, global assessment, and refractoriness to treatment. Factors associated with adverse outcomes in uveitis were studied using linear regression. For categorical factors, marginal averages and their standard errors are displayed together with linear regression coefficients with 95% confidence intervals (CI). For continuous factors, averages and standard deviations are reported in addition to linear regression coefficients with 95% CI. Two regression coefficients are reported for each variable: unadjusted and adjusted for age at diagnosis and sex. Results 250 uveitis outbreaks were included. 62 uveitis outbreaks (31%) were classified as severe, 42 as moderate (21%), and 93 as mild (47%) based on the definition and construction of outcome score. The results of the linear regression model revealed that the uveitis activity was more severe in patients with smoking history (β = 0.34), axial and peripheral involvement (β = 0.43), a BASDAI>4 (β = 0.32), positive HLA-B27 (β = 0.29), female sex (β = 0.19), patients with CRP elevation (β = 0.002) and bilateral ocular involvement (β = 0.32). At the same time, shorter disease evolution (β=-0.02) was associated with less severe uveitis activity. Conclusion We have determined factors associated with adverse outcomes in SpA-U by developing an outcome score that integrates ocular inflammatory activity, visual acuity, global assessment, and refractoriness to treatment. Disclosure C. Sieiro Santos: None. I. Sendino Tenorio: None. C. Álvarez Castro: None. E. Díez Álvarez: None.